Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Abstract Background Treatment of hepatocellular carcinoma (HCC) varies widely depending on the patient's condition. In recent years, combination therapy with immune checkpoint inhibitors has emerged as the treatment of choice due to its superior antitumor effects for unresectable HCC (uHCC). Co...

Full description

Bibliographic Details

Published in:	Surgical Case Reports
Main Authors:	Ryosuke Tsunemitsu, Motoyasu Tabuchi, Shinya Sakamoto, Kenta Ogi, Manabu Matsumoto, Jun Iwata, Takehiro Okabayashi
Format:	Article
Language:	English
Published:	Japan Surgical Society 2023-06-01
Subjects:	Advanced hepatocellular carcinoma Conversion surgery Atezolizumab plus bevacizumab
Online Access:	https://doi.org/10.1186/s40792-023-01678-9